PfizerДлинная
BUY $PFE - NRPicks Ene 17
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. Pfizer mainly sells prescription drugs and vaccines, also spends a leading amount on research and development, close to $8 billion annually.
The company has developed its COVID-19 vaccine, however, it has not reflected its optimism in the stock price. The company has generated the same income quarter by quarter during the year, so we can see a good future for the development of its vaccine and the development of the new strain of the virus.
Fundamentals:
- Value
- P/B 3.1x VS 4.3x Industry
- ROE 22% vs. 17% industry
Technicians:
- Price level below SMA 250-200-150
- Williams R% at -50% levels
- RSI (40) Midlevel
- +1% average upside during the month
As a result of the allergic reactions to the vaccine presented, PFE presented a 15% correction from December 8 to December 31, which stopped at a support of $36.3. From this point on, the stock presented a change in trend, which could continue due to the fact that the stock is below its medium term moving average.
The company has developed its COVID-19 vaccine, however, it has not reflected its optimism in the stock price. The company has generated the same income quarter by quarter during the year, so we can see a good future for the development of its vaccine and the development of the new strain of the virus.
Fundamentals:
- Value
- P/B 3.1x VS 4.3x Industry
- ROE 22% vs. 17% industry
Technicians:
- Price level below SMA 250-200-150
- Williams R% at -50% levels
- RSI (40) Midlevel
- +1% average upside during the month
As a result of the allergic reactions to the vaccine presented, PFE presented a 15% correction from December 8 to December 31, which stopped at a support of $36.3. From this point on, the stock presented a change in trend, which could continue due to the fact that the stock is below its medium term moving average.
Отказ от ответственности
Все виды контента, которые вы можете увидеть на TradingView, не являются финансовыми, инвестиционными, торговыми или любыми другими рекомендациями. Мы не предоставляем советы по покупке и продаже активов. Подробнее — в Условиях использования TradingView.